What Austedo Treats: Main Uses and Benefits

The medication is commonly used for the symptomatic management of specific, involuntary motor symptoms associated with hyperkinetic movement disorders in adults. It provides supportive relief by moderating excessive and uncontrolled motions that disrupt daily life. It is indicated for two primary therapeutic domains: chorea associated with Huntington's disease and tardive dyskinesia in adults.

Symptomatic Relief Domains

This treatment is applied to address symptoms of increased neurological or muscular activity, presenting as unpredictable, rapid, and often jerky movements. It is considered relevant in clinical settings that involve acute or unstable symptom patterns. Symptomatic relief may assist with managing symptoms that interfere with daily functioning and provides support that helps ease the overall symptom burden.

“It is commonly used across conditions presenting with disruptive symptom manifestations.”

The medication is also commonly used to help with abnormal movements in the face, tongue, and body associated with tardive dyskinesia. This application is relevant for easing symptoms that interfere with daily functioning.

Quick Fact: Relief for Motor Symptoms
Is relevant for easing symptoms of increased neurological or muscular activity, helping to maintain a sense of stability when symptoms are more noticeable.

Who Can and Cannot Use Austedo?

The eligibility for Austedo (deutetrabenazine) is strictly governed by regulatory documentation and defines both who is approved to use the medicine and who must avoid it. It is approved for use only in adults.

Absolute Prohibitions (Contraindications)

Official regulatory labels indicate that Austedo is contraindicated and must not be used in the following populations:

• Hepatic Impairment: Patients with any degree of liver dysfunction.
• Neuropsychiatric Risk: Patients who are suicidal or have untreated/inadequately treated depression (in the context of Huntington's disease).
• Concurrent Drug Use: Patients taking other VMAT2 inhibitors (tetrabenazine or valbenazine), monoamine oxidase inhibitors (MAOIs), or reserpine.

---

Condition- and Age-Specific Restrictions

Population Group	Regulatory Status and Constraint
Pediatric Patients	Safety and efficacy have not been established; use is restricted to adults.
Cardiac Conditions	Use must be avoided in patients with congenital long QT syndrome or a history of related arrhythmias.
Metabolic Status	Poor CYP2D6 metabolizers must have a maximum daily dosage not exceeding 36 mg.
Pregnancy/Lactation	No adequate human data exists; use requires careful risk assessment.

Older adults may use the medicine but require cautious dose selection due to the frequency of coexisting conditions.

Interactions with other medicines and products

Austedo (deutetrabenazine) has specific interaction restrictions due to its effects on monoamine levels and its metabolism by liver enzymes.

Contraindicated and Restricted Combinations

The following medications or drug classes should not be used concurrently with Austedo:

• VMAT2 Inhibitors (e.g., Tetrabenazine, Valbenazine): Concomitant use is contraindicated due to an increased risk of adverse effects.
• Monoamine Oxidase Inhibitors (MAOIs): Use is contraindicated. A washout period of at least 14 days is required after stopping an MAOI before starting Austedo.
• Reserpine: Use is contraindicated. A washout period of at least 20 days is required after stopping reserpine before starting Austedo.

Drug Interactions Requiring Dose Adjustments

Concomitant use of strong CYP2D6 inhibitors (e.g., quinidine, paroxetine, fluoxetine, bupropion) significantly increases the exposure to Austedo's active metabolites. When used with strong CYP2D6 inhibitors, or in patients identified as CYP2D6 poor metabolizers, the total daily dose of Austedo must not exceed 36 mg.

Other Significant Interactions

• Drugs that Prolong the QTc Interval: Co-administration may result in clinically significant QT prolongation. Avoid use in patients with congenital long QT syndrome or a history of cardiac arrhythmias.
• Neuroleptic Drugs/Antipsychotics and Dopamine Antagonists: Use may increase the risk of serious adverse events, including Neuroleptic Malignant Syndrome (NMS), akathisia, and parkinsonism.
• Alcohol and Other Sedating Drugs: Co-administration can have additive sedative and somnolence effects.

The mechanism of deutetrabenazine centers on the precise molecular regulation of neurotransmitter availability within the central nervous system (CNS). The resulting dampening of excessive signaling within key motor pathways is the core physiological consequence of the mechanism.

Reversible Inhibition of VMAT2 Transporter

The primary action begins with the drug's active metabolites acting as a reversible inhibitor of the Vesicular Monoamine Transporter 2 (VMAT2), a protein critical for neurotransmitter storage. By blocking VMAT2, the drug prevents monoamines, particularly dopamine, from being packaged into synaptic vesicles. This fundamental action modifies the capacity of neurons to release signals, thereby modulating systems that rely on regulated monoamine transmission.

Functional Depletion of Presynaptic Monoamines

The failure to store monoamines in vesicles causes them to remain in the neuronal cytoplasm, where they are rapidly metabolized and degraded by enzymes like Monoamine Oxidase (MAO). This leads to the functional depletion of presynaptic monoamine stores. This mechanistic cascade modifies early molecular steps that ultimately shape systemic physiological outcomes by reducing the overall amount of chemical messenger available for transmission, resulting in a reduction of excessive output from motor control pathways.

Mechanism-Sustained Action via Deuteration

The unique structural feature of deuteration chemically alters the active metabolites, slowing down their breakdown rate. This consistency ensures the VMAT2 inhibition is sustained, promoting continuous functional modulation within the targeted pathways.

How to Use Austedo (Deutetrabenazine)

This section outlines the administration and dosage instructions for Austedo.

Administration and Dosing

Feature	AUSTEDO (Immediate-Release)	AUSTEDO XR (Extended-Release)
Route of Administration	Oral	Oral
Starting Dose	12 mg per day (6 mg taken twice daily)	12 mg once daily
Maximum Daily Dose	48 mg	48 mg
Timing with Food	Must be taken with food	May be taken with or without food
Frequency	12 mg or more must be taken in two divided doses per day	Once daily

Titration and Tablet Integrity

The dosage is initiated at a low dose and must be increased gradually at weekly intervals in increments of 6 mg per day to reach the patient's intended maintenance dose. The maximum recommended dose is 48 mg per day. The tablets must be swallowed whole; they should not be chewed, crushed, or broken.

Treatment Interruption and Special Rules

If the medicine is stopped for more than one week, the dosage must be re-titrated from the starting dose when resuming treatment. If the interruption is less than one week, the previous maintenance dose may be resumed. For individuals who are taking strong CYP2D6 inhibitors (such as certain antidepressants), the total daily dosage must not exceed 36 mg.

Research evidence / Overview of Studies for Austedo

This section describes the structure of the official research evidence for Austedo (deutetrabenazine), outlining the types of studies that have been conducted for its approved uses in adults, the outcomes they measured, and areas where data remain limited or uncertain. This information is a research overview and is not intended to offer clinical advice or personal recommendations.

---

Evidence for Chorea Associated with Huntington's Disease

The core research base for chorea associated with Huntington’s Disease (HD) consists primarily of short-term, randomized, double-blind, placebo-controlled trials. These trials were used in research exploring how symptoms change over time.

Researchers monitored adult patients with HD and examined the severity of their involuntary movements using specialized clinical rating scales. The main outcome measured was the change in the UHDRS-TMC (Total Maximal Chorea) score, which is relevant in evidence describing how movement symptoms are measured.

Studies reported differences in the measured movement scores between the treatment group and the placebo group over the 12-week trial period. These controlled trials were structured with a consistent research design over the short term, but they primarily focused on chorea and provide limited insight into outcomes related to systemic or functional imbalance or the underlying progression of the disease.

---

Evidence for Tardive Dyskinesia

For tardive dyskinesia (TD), the evidence is also based on several short-term, randomized, double-blind, placebo-controlled trials conducted in adults. These research scenarios focused on episodes where symptoms become more noticeable.

The core research examined the change in the severity of abnormal, uncontrollable movements using the AIMS (Abnormal Involuntary Movement Scale) total score, which is relevant in evidence describing how symptoms are measured. Studies explored outcomes reflecting daily functioning or activity level and outcomes related to physical discomfort. Trials documented measured changes in the AIMS scores over the 12-week controlled period.

Studies for TD included patients with diverse underlying psychiatric conditions who continued on their existing mental health medications throughout the research period. This means the research was applied in settings evaluating daily-life functioning for patients with conditions characterized by functional limitations.

---

Long-Term Research and Follow-up Duration

The primary controlled trials for both HD chorea and TD symptoms had follow-up durations that were limited to 12 weeks. To gather information beyond 12 weeks, researchers conducted open-label extension studies where all enrolled patients received the treatment.

Because these extended observation periods were not compared to a placebo, the long-term effects are not fully established under the same controlled conditions as the initial trials. The data provide context on long-term usage; however, the lack of a control group means these findings have limitations compared to the original short-term, randomized findings.

---

Key Research Gaps and Uncertainties

While evidence from controlled trials exists for both approved indications, regulatory evaluations and scientific reviews point to areas where research is still needed.

• Short-Term Focus: The core evidence is focused on short-term symptom changes over a defined time interval of 12 weeks. The data available for very long-term symptom management is still developing and is not based on controlled trials.
• Comparative Research: Comparative evidence is lacking in terms of direct, head-to-head research that systematically monitors and reports outcomes against other similar VMAT2 inhibitor medications.
• Beyond Motor Symptoms: For HD chorea, the existing studies provide limited information regarding research outcomes related to non-motor symptoms such as thinking, cognition, or overall functional capacity, as the research primarily examined movement severity.

Key Studies & References

1. MedlinePlus Drug Information: Deutetrabenazine

Common questions about Austedo (FAQ)

Q: Is Austedo used for anything besides movement disorders?

Official regulatory documents indicate that Austedo is approved only for the treatment of two specific movement disorders: chorea associated with Huntington’s disease and tardive dyskinesia.

Q: What are the most common side effects of Austedo that people talk about?

Based on the official product information from clinical trials, the most commonly reported adverse events include central nervous system effects such as sleepiness (somnolence) and fatigue. Other frequently observed effects include diarrhea and dry mouth.

Q: Are there any foods or drinks I should avoid while taking Austedo?

Official product information notes that the use of alcohol should be avoided or limited while taking this medicine. This is because alcohol may increase side effects like dizziness and drowsiness. Regulatory documents do not specify any other particular food restrictions.

Q: What happens if you miss a dose of Austedo?

Official patient information addresses what to do for a missed dose, noting that if the medicine is stopped for more than seven days, it may require a healthcare professional's guidance before resuming treatment.

Q: Does Austedo cause weight gain or weight loss?

Weight changes have been reported as adverse events in clinical studies, including instances of weight increase. These changes were observed in some patients during the studies.

Q: Can Austedo affect sleep patterns, like insomnia or vivid dreams?

The official product information lists insomnia (difficulty sleeping) as a common side effect. Vivid dreams are not explicitly listed in the official adverse reactions documentation.

Q: Can people who are pregnant or breastfeeding use Austedo?

Official labeling states there are no adequate human data on the use of Austedo during pregnancy. Based on animal studies, there is potential for harm to the fetus. It is also unknown whether the medicine passes into human breast milk or affects a nursing infant.

Q: Are there any known interactions between Austedo and supplements?

Official drug interaction warnings focus on prescription medications that affect the CYP2D6 liver enzyme, cause QTc prolongation, or cause sedation. The official product information does not list specific supplements, but the identified interactions provide context for potential risks with products affecting the same systems.

Q: What is the success rate of Austedo for tardive dyskinesia?

Clinical trials for tardive dyskinesia measured the drug's effectiveness by monitoring the reduction of involuntary movements using a clinical assessment tool called the Abnormal Involuntary Movement Scale (AIMS). The studies found a measured reduction of involuntary movements using the AIMS score in the group taking the medicine compared to the group taking a placebo.

Q: Is Austedo a daily medication or taken as needed?

Austedo is described in the official dosing information as a medication intended for daily administration. It is used for ongoing symptom management and is not prescribed on an as-needed basis.

Q: What happens in the body when Austedo starts to work?

Austedo's mechanism involves reversibly inhibiting the VMAT2 protein within nerve cells. This action leads to a reduction of chemical messengers (like dopamine) that are released, which helps to slow down or moderate excessive signaling in the brain's motor pathways.

Storage and Environmental Control

Austedo tablets must be stored in a tightly closed container at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). The regulatory labeling permits temporary temperature excursions between 59 F and 86 F (15 C and 30 C). The medication must be protected from light, moisture, and excessive heat, and should not be frozen.

Child-Protection and Disposal Requirements

Official labeling requires keeping Austedo tablets and all medications out of the reach and sight of children and pets. Do not keep medicine that is outdated or no longer needed. Unused or expired medication should be disposed of by consulting a healthcare professional or pharmacist, who can advise on local drug take-back programs or safe disposal methods.